Cannabix Technologies Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cannabix Technologies (BLO) has started its Contactless Alcohol Breathalyzer (CAB) pilot program in Montana
  • Friedel Clinic, based in Montana, will begin piloting the breathalyzer
  • The high-volume clinic has a diverse range of patients and focuses on private-sector testing for alcohol and illicit drugs
  • Last fall, Cannabix Technologies developed versions of the CAB technology for wall-mounted and in-vehicle applications in workplaces and vehicles
  • Cannabix Technologies (BLO) is down 3.61 per cent, trading at $0.40 per share as of 2:30 p.m. EST

Breath testing device developer, Cannabix Technologies (BLO), has started its Contactless Alcohol Breathalyzer (CAB) pilot program in Montana.

The company stated that Friedel Clinic will begin piloting the breathalyzer. The Friedel Clinic is one of the top drug testing providers within the state of Montana. The high-volume clinic also has a diverse range of patients and focuses on private-sector testing for alcohol and illicit drugs.

Last fall, Cannabix Technologies developed versions of the CAB technology for wall-mounted and in-vehicle applications in workplaces and vehicles.

Montana Senator Chris Friedel stated,

“The Friedel Clinic has been a pioneer in alcohol, drug and brain health testing in the state of Montana… we are excited to see how the Cannabix Contactless Alcohol Breathalyzer devices can enhance safety in both workplace and in-vehicle settings – in particular the potential to disrupt legacy alcohol interlock methods which have seen little innovation over the last 40 years.”

The wall-mounted CAB has been designed for employers who need to use a “pre-access” test for alcohol consumption before and during work hours. This technology allows a user to direct a single breath sample toward a small vent integrated into an indoor unit or behind the steering wheel of a car. Both applications are completely contactless.

The company stated its CAB is different than existing systems because it does not require the use of a mouthpiece or straw to directly blow into a handheld device. Additionally, the CAB also provides a warning, pass, or fail result along with a blood alcohol content level on the screen for the driver to see.

Cannabix Technologies (BLO) is down 3.61 per cent, trading at $0.40 per share as of 2:30 p.m. EST.


More From The Market Herald
The Market Herald Video

" Datametrex (TSXV:DM) details exciting initiatives ahead

Datametrex (DM) has issued a corporate update as of March 2023.

" Innocan Pharma (CSE:INNO) reports successful efficacy test for vaginal derma product

Innocan Pharma (INNO) has announced successful results from a controlled efficacy test of its vaginal derma product.

" @ the Bell: TSX bounces back again

Euro banking drama had a ripple effect felt on Bay Street Friday but Canada’s main stock index dodged another close in the red.
RBC

" Survey shows fraud risk a rising concern for Canadians

Latest survey by Royal Bank of Canada shows Canadians are concerned about spotting scams and that fraud risk will get worse if a recession